Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma
- 18 May 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 69 (10) , 2041-2051
Abstract
Recently, the effectiveness of anti-programmed death 1 (PD-1) antibody therapy in the treatment of renal cell carcinoma (RCC) has been established. Nevertheless, efficacy has been reported to be limited to only 10–30% of patients. To develop more effective immunotherapy for RCC, we analyzed the immunological characteristics in RCC tissues by immunohistochemistry (IHC). We prepared a tissue microarray that consisted of tumor tissue sections (1 mm in diameter) from 83 RCC patients in Kanagawa Cancer Center between 2006 and 2015. IHC analysis was performed with antibodies specific to immune-related (CD8 and Foxp3) and immune checkpoint (programmed death ligand 1 (PD-L1) and 2 (PD-L2), B7-H4 and galectin-9) molecules. The numbers and proportions of positively stained tumor cells or immune cells were determined in each section. From multivariate analysis of all 83 patients, higher galectin-9 expression was detected as a factor associated with worse overall survival (OS) (P = 0.029) and that higher stage and higher B7-H4 expression were associated with worse progression-free survival (PFS) (P < 0.001 and P = 0.021, respectively). Similarly, in multivariate analysis of 69 patients with clear cell RCC, though not statistically significant, there was a trend for association between higher galectin-9 expression and worse OS (P = 0.067), while higher stage was associated with worse PFS (P < 0.001). This study suggests that higher galectin-9 expression is an independent adverse prognostic factor of OS in RCC patients. Therefore, to develop more effective personalized immunotherapy to treat RCC, it may be important to target not only PD-1/PD-L1, but also other immune checkpoint molecules such as galectin-9.Keywords
Funding Information
- Kanagawa Cancer Center Hospital-Research Institute Joint Study
This publication has 45 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- Galectin-9 expression links to malignant potential of cervical squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survivalProceedings of the National Academy of Sciences, 2006
- Restoring function in exhausted CD8 T cells during chronic viral infectionNature, 2005
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005
- Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast CancerClinical Cancer Research, 2005
- Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significanceInternational Journal of Cancer, 2002